REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of REGENXBIO (NASDAQ:RGNX) from a sell rating to a hold rating in a report released on Friday morning.

A number of other research analysts have also recently issued reports on the stock. Raymond James started coverage on shares of REGENXBIO in a report on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective for the company. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Morgan Stanley restated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $33.88.

REGENXBIO Price Performance

Shares of NASDAQ RGNX opened at $6.34 on Friday. The stock has a market capitalization of $314.12 million, a P/E ratio of -1.26 and a beta of 1.29. The company has a 50-day moving average price of $7.46 and a 200-day moving average price of $9.28. REGENXBIO has a 1 year low of $5.62 and a 1 year high of $24.26.

Institutional Trading of REGENXBIO

Several hedge funds have recently added to or reduced their stakes in the stock. Alpine Global Management LLC bought a new stake in REGENXBIO in the fourth quarter worth about $175,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in REGENXBIO by 9.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company’s stock worth $558,000 after acquiring an additional 6,105 shares during the period. Two Sigma Advisers LP raised its position in shares of REGENXBIO by 164.7% in the fourth quarter. Two Sigma Advisers LP now owns 180,000 shares of the biotechnology company’s stock valued at $1,391,000 after purchasing an additional 112,000 shares during the period. Two Sigma Investments LP raised its position in shares of REGENXBIO by 209.2% in the fourth quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company’s stock valued at $3,010,000 after purchasing an additional 263,495 shares during the period. Finally, Rafferty Asset Management LLC raised its position in shares of REGENXBIO by 22.4% in the fourth quarter. Rafferty Asset Management LLC now owns 93,821 shares of the biotechnology company’s stock valued at $725,000 after purchasing an additional 17,180 shares during the period. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.